Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
PHVS affiliate files Rule 144 notice to sell 2,292 shares of Common Stock appearing as Restricted Stock Units with an intended sale date of 04/11/2026. The filing also reports prior 10b5-1 sales of 23,333 shares on 04/08/2026 for $647,283.26.
Pharvaris N.V. Principal Accounting Officer Anna Nijdam reported a routine tax-related share disposition. On the vesting of restricted stock units, the issuer withheld 548 shares of common stock at $26.63 per share to cover tax withholding obligations. After this withholding, Nijdam directly holds 48,940 common shares.
Pharvaris N.V. Chief Executive Officer Berndt Modig reported open-market sales of a total of 23,333 shares of common stock on April 9, 2026. The transactions were executed under a Rule 10b5-1 trading plan at weighted average prices of $27.7352 and $28.415 per share, across price ranges of $27.31–$28.30 and $28.32–$28.51. The shares sold include stock previously acquired upon vesting of restricted stock units. Following these sales, Modig holds 142,084 shares directly and 950,000 shares indirectly through Schoodif Management BV.
Pharvaris N.V. Principal Accounting Officer Anna Nijdam had 1,167 shares of Common Stock withheld by the company at $28.56 per share to cover tax obligations upon the vesting of restricted stock units. After this tax-withholding disposition, she directly holds 49,488 shares.
Pharvaris N.V.’s Principal Accounting Officer Anna Nijdam reported a routine tax-related share disposition. On the vesting of restricted stock units, 1,164 shares of common stock were withheld by the company at $28.25 per share to cover tax withholding obligations. After this withholding, Nijdam directly holds 50,655 shares of Pharvaris common stock. This was not an open-market sale but an administrative step tied to equity compensation.
Pharvaris N.V. insider Stefan Andreas Abele, Chief Technical Ops Officer, filed an amended ownership report. The amendment corrects his holdings to reflect 49,216 shares of Common Stock beneficially owned directly after certain restricted stock units vested and related tax settlement timing delayed their appearance in the original filing.
Pharvaris N.V., a Netherlands-based late-stage biopharmaceutical company, files its annual report outlining risks and strategy as it advances deucrictibant in immediate-release capsules and extended-release tablets for hereditary angioedema (HAE). The company remains pre-revenue, has incurred significant losses and expects continued operating losses for several years.
Pharvaris emphasizes heavy dependence on deucrictibant, notes prior U.S. clinical holds that were lifted after additional toxicology work, and highlights potential delays or failures in late-stage trials. It reports 65,210,590 ordinary shares outstanding as of December 31, 2025, and warns that additional capital will be needed, potentially diluting shareholders or forcing pipeline cuts.
Pharvaris reported a larger 2025 loss while advancing its late-stage HAE pipeline. Cash and cash equivalents were €291.7 million as of December 31, 2025, up from €281 million a year earlier, supporting ongoing Phase 3 programs.
R&D expenses rose to €34.1 million in the fourth quarter and €124.5 million for 2025, reflecting investment in pivotal studies, while G&A expenses were €13.5 million in the quarter and €45.3 million for the year. The company reported a fourth-quarter loss of €46.7 million and a full-year loss of €175.7 million, with basic and diluted loss per share of €0.72 and €2.97, respectively.
Pharvaris completed enrollment in CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for prophylactic treatment of hereditary angioedema (HAE), with topline data anticipated in the third quarter of 2026, and plans to submit a U.S. NDA for deucrictibant IR for on-demand HAE treatment in the first half of 2026.
Pharvaris N.V. director Robert Glassman filed an initial ownership report showing his existing equity position. He reports several stock option awards on common stock, including options over 16,500 shares at an exercise price of $28.00, 15,000 shares at $16.05, 14,000 shares at $22.31, 21,000 shares at $8.05, 14,493 shares at $18.14, and 8,000 shares at $20.00, with expirations between 2031 and 2036. He also holds 23,300 option-underlying shares at $7.89 and 15,167 shares of common stock directly, plus 5,500 restricted stock units that will fully vest on March 3, 2027.